Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

The significant expenses included in Operating Income, as regularly provided to the CODM, are as follows (in millions):



	Three Months Ended March 31, 2026						Three Months Ended March 31, 2025
	SNS		PM&R		Total		SNS		PM&R		Total
Net Sales	$	124.0	$	56.3	$	180.3	$	101.1	$	56.2	$	157.3
Reconciliation of consolidated net sales:					—
Corporate and other(a)					1.9						10.2
Total consolidated net sales					$	182.2					$	167.5
Cost of goods sold	(48.0)		(21.7)				(35.2)		(20.7)
Distribution	(7.1)		(3.2)				(6.3)		(2.7)
Research and development expenses	(3.7)		(1.3)				(4.1)		(1.1)
Advertising, promotion and selling expenses	(15.1)		(15.9)				(11.8)		(14.9)
General expenses	(20.8)		(12.3)				(17.5)		(12.7)

Depreciation and amortization expense	(6.1)		(3.7)				(5.0)		(3.9)
Other segment items	(0.1)		—				(0.1)		—
Reportable segment operating income (loss)	$	23.1	$	(1.8)	$	21.3	$	21.1	$	0.2	$	21.3
Corporate and other					(12.4)						(11.0)
Interest expense, net					(1.3)						(0.6)
Income before income taxes					$	7.6					$	9.7

__________________________________________________

(a)Corporate and other net sales includes revenue from our IV infusion oncology pumps.